Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
476 studies found for:    Study of MK-3475
Show Display Options
Rank Status Study
1 Recruiting Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors
Conditions: MSI Positive Colorectal Cancer;   MSI Negative Colorectal Cancer;   MSI Positive Non-Colorectal Cancers
Intervention: Drug: MK-3475
2 Recruiting MK-3475/BCG in High Risk Superficial Bladder Cancer
Condition: Bladder Cancer
Intervention: Drug: Intravenous MK-3475/ Intravesical BCG
3 Recruiting Study of MK-3475 in Relapsed or Refractory Peripheral T-cell Non-Hodgkin Lymphoma
Condition: Lymphoma, T-Cell, Peripheral
Intervention: Drug: MK-3475
4 Active, not recruiting Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)
Condition: Head and Neck Squamous Cell Carcinoma (HNSCC)
Intervention: Biological: pembrolizumab
5 Active, not recruiting Study of MK-3475 (Pembrolizumab) Versus Platinum-based Chemotherapy for Participants With PD-L1-positive Advanced or Metastatic Non-small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)
Condition: Non-small Cell Lung Cancer
Interventions: Biological: pembrolizumab;   Drug: carboplatin;   Drug: paclitaxel;   Drug: pemetrexed
6 Active, not recruiting
Has Results
Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041)
Condition: Melanoma
Intervention: Biological: Pembrolizumab
7 Active, not recruiting Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:
Condition: Clear Cell Renal Carcinoma
Interventions: Drug: MK-3475;   Drug: Bevacizumab
8 Recruiting MK-3475 in Patients With Thymic Carcinoma
Condition: Thymic Carcinoma
Intervention: Drug: MK-3475
9 Recruiting Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer
Conditions: Recurrent Merkel Cell Carcinoma;   Stage IIIA Merkel Cell Carcinoma;   Stage IIIB Merkel Cell Carcinoma;   Stage IV Merkel Cell Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
10 Active, not recruiting Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)
Conditions: Cancer;   Solid Tumor
Intervention: Biological: Pembrolizumab
11 Active, not recruiting Pembrolizumab in Treating Patients With Extensive Stage Small Cell Lung Cancer After Completion of Combination Chemotherapy
Condition: Extensive Stage Small Cell Lung Carcinoma
Interventions: Biological: Pembrolizumab;   Other: Laboratory Biomarker Analysis
12 Active, not recruiting Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer
Condition: Stage IV Prostate Cancer
Interventions: Procedure: Cryosurgery;   Drug: Degarelix;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
13 Active, not recruiting Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome
Conditions: Recurrent Mycosis Fungoides and Sezary Syndrome;   Stage IB Mycosis Fungoides and Sezary Syndrome;   Stage IIA Mycosis Fungoides and Sezary Syndrome;   Stage IIB Mycosis Fungoides and Sezary Syndrome;   Stage IIIA Mycosis Fungoides and Sezary Syndrome;   Stage IIIB Mycosis Fungoides and Sezary Syndrome;   Stage IVA Mycosis Fungoides and Sezary Syndrome;   Stage IVB Mycosis Fungoides and Sezary Syndrome
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
14 Recruiting MK-3475 With Lymphodepletion, TIL and High or Low Dose Interleukin-2 (IL-2)
Condition: Melanoma
Interventions: Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Fludarabine;   Procedure: TIL (T-cells);   Drug: IL-2;   Drug: MK-347;   Behavioral: Questionnaires;   Behavioral: Phone Calls
15 Recruiting Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms
Conditions: AIDS-Related Non-Hodgkin Lymphoma;   Classical Hodgkin Lymphoma;   HIV Infection;   Locally Advanced Malignant Neoplasm;   Metastatic Malignant Neoplasm;   Recurrent Hepatocellular Carcinoma;   Recurrent Hodgkin Lymphoma;   Recurrent Kaposi Sarcoma;   Recurrent Malignant Neoplasm;   Recurrent Melanoma of the Skin;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Non-Small Cell Lung Carcinoma;   Refractory Hodgkin Lymphoma;   Refractory Malignant Neoplasm;   Solid Neoplasm;   Stage IIIA Hepatocellular Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Skin Melanoma;   Stage IIIB Hepatocellular Carcinoma;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIB Skin Melanoma;   Stage IIIC Hepatocellular Carcinoma;   Stage IIIC Skin Melanoma;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Skin Melanoma;   Stage IVA Hepatocellular Carcinoma;   Stage IVB Hepatocellular Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
16 Active, not recruiting
Has Results
Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025)
Condition: Non-small Cell Lung Cancer
Intervention: Biological: Pembrolizumab
17 Recruiting MK-3475 in Melanoma and NSCLC Patients With Brain Metastases
Conditions: Melanoma;   Non-Small Cell Lung Cancer;   Brain Metastases
Intervention: Drug: MK-3475
18 Recruiting MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: MK-3475;   Drug: Gemcitabine
19 Active, not recruiting A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)
Condition: Non-small Cell Lung Carcinoma
Interventions: Biological: Pembrolizumab;   Drug: Paclitaxel;   Drug: Carboplatin;   Biological: Bevacizumab;   Drug: Pemetrexed;   Biological: Ipilimumab;   Drug: Erlotinib;   Drug: Gefitinib
20 Recruiting Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)
Conditions: Solid Tumor;   Non-small Cell Lung Cancer;   Small Cell Lung Cancer
Interventions: Biological: Pembrolizumab 2 mg/kg;   Biological: Pembrolizumab 10 mg/kg;   Biological: Pembrolizumab 200 mg;   Drug: Cisplatin 75 mg/m^2;   Drug: Pemetrexed 500 mg/m^2;   Drug: Carboplatin AUC 5 mg/mL/min;   Drug: Carboplatin AUC 6 mg/mL/min;   Drug: Paclitaxel 200 mg/m^2;   Drug: Nab-paclitaxel 100 mg/m^2;   Biological: Ipilimumab 1 mg/kg;   Drug: Etoposide 100 mg/m^2

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.